2 weeks Ago
Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) Q3 2024 Earnings Conference Call November 5, 2024 5:00 PM ET Company Participants Joshua Higa - VP, IR Emil Kakkis - CEO and President Erik Harris - CCO Howard Horn - CFO Eric Crombez - CMO Conference Call Participants Chris Raymond - Piper Sandler Tazeen Ahmad - Bank of America Malcolm Kuno - JPMorgan Gena Wang - Barclays Lydia Erdman - Goldman Sachs Maury Raycroft - Jefferies Mehdi Goudarzi - Truist Securities Yaron Werber - TD Cowen Yigal Nochomovitz - Citi Thomas Yip - H.C.
Wainwright Jack Allen - Baird Joe Schwartz - Leerink Partners Michael Riad - Morgan Stanley Kristen Kluska - Cantor Fitzgerald Dae Gon Ha - Stifel Operator Good afternoon and welcome to the Ultragenyx Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. At the end of the prepared remarks, you will have opportunity to ask questions during the question-and-answer portion of the call.
It is now my pleasure to turn the call to Joshua Higa, Vice President of Investor Relations. Joshua Higa Thank you. We have issued a press release detailing our financial results, which you can find on our website at ultragenyx.
com. Joining me on this call are Emil Kakkis, Chief Executive Officer and President; Erik Harris, Chief Commercial Officer; Howard Horn, Chief Financial Officer; and Eric Crombez, Chief Medical Officer. I'd like to remind everyone that during today's call, we will be making forward-looking statements.
These statements are subject to certain risks and uncertainties and our actual results may differ materially. Please refer to the risk factors discussed in our latest SEC filings. I'll now turn the call over to Emil.
Emil Kakkis Thanks Josh and good afternoon everyone. This is a great time for Ultragenyx as we successfully completed development work.
